MICVO (micvotabart pelidotin) — Interim data
H1 2027
Updated overall survival data from the MICVO monotherapy study are expected in the first half of 2027.Source filing
PYXS biotech catalysts & pipeline
PYXIS ONCOLOGY INC · Data as of 2026-10-27
Upcoming catalysts
MICVO (micvotabart pelidotin) — FDA meeting
Q1 2027
An End of Phase 2 meeting with the FDA to align on dose selection is anticipated in the first quarter of 2027.Source filing
MICVO (micvotabart pelidotin) — Clinical data readout
H2 2027
Additional data evaluating initial durability and selection of the recommended Phase 3 dose (RP3D) for the 1L combination are expected in the second half of 2027.Source filing
MICVO (micvotabart pelidotin) — Conference presentation
Nov 18
In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium's antibody-drug conjugates session.Source filing
MICVO (micvotabart pelidotin) — Conference presentation
Nov 19
Pyxis Oncology BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.Source filing